8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 23, 2008)

Filed January 23, 2008For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on January 23, 2008, to announce its financial results for the fourth quarter and full year of 2007. The report primarily serves to furnish a press release detailing these results. While the specific financial figures are not detailed within the 8-K itself, it indicates that Abbott's management will be discussing non-GAAP financial measures, such as net earnings and diluted earnings per share, excluding specified items. These exclusions are noted to include factors like merger-related costs, purchase accounting adjustments, restructuring and impairment charges, certain litigation charges, and the impact of regulatory changes. Investors are advised that Abbott's management believes these non-GAAP measures offer a more insightful view of ongoing business performance by removing unusual or unpredictable factors. However, the company explicitly cautions that these non-GAAP figures should be considered alongside, and not as a replacement for, the standard GAAP financial measures. This filing signals the release of key performance data and management's perspective on the underlying operational health of the company for the period.

Key Highlights

  • 1Abbott Laboratories announced its Q4 and full-year 2007 financial results via an 8-K filing on January 23, 2008.
  • 2The primary purpose of the 8-K filing is to furnish a press release containing the company's financial performance data.
  • 3The company will be presenting non-GAAP financial measures, including adjusted net earnings and EPS.
  • 4These non-GAAP measures exclude items such as merger-related costs, purchase accounting adjustments, restructuring charges, and litigation expenses.
  • 5Management believes these non-GAAP metrics provide a clearer view of ongoing business performance.
  • 6Abbott cautions investors to consider non-GAAP measures in conjunction with, not as a substitute for, GAAP results.
  • 7The filing includes Exhibit 99.1, which is the press release dated January 23, 2008.

Frequently Asked Questions

This 8-K filing does not contain the specific financial results directly. Instead, it announces that Abbott Laboratories issued a press release on January 23, 2008, detailing its results for the fourth quarter and full year of 2007. Investors would need to refer to the furnished press release (Exhibit 99.1) for the actual financial figures.

Abbott's management indicated that these specified items are factors that are unusual or unpredictable. Examples provided in the filing include merger-related costs, purchase accounting adjustments, restructuring and impairment charges, certain litigation charges, and the impact of changes in laws and regulations.

Abbott's management believes that presenting non-GAAP financial measures, which exclude certain items, provides useful information to investors. They contend that these measures allow investors to better evaluate the company's ongoing business performance by removing the impact of unusual or unpredictable events.

Abbott explicitly cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, the financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). This means investors should look at both standard GAAP results and the adjusted non-GAAP figures to get a comprehensive understanding of the company's financial health.